Taken together, these results suggest that, despite some promising data as further reported below, DPP-4 inhibitors should be considered a second choice as compared to GLP-1 RA or SGLT2i in patients with T2D and PAD. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.